PetIQ (PETQ) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is PetIQ Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of PetIQ is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of PetIQ's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, PetIQ's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PetIQ's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PetIQ's Risk Assessment distribution charts can be found below:

* The bar in red indicates where PetIQ's Risk Assessment falls into.

PetIQ (NAS:PETQ) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

PetIQ Risk Assessment Related Terms

Thank you for viewing the detailed overview of PetIQ's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

PetIQ (PETQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

39L:Germany

Address

230 East Riverside Drive, Eagle, ID, USA, 83616

Website

https://www.petiq.com

PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Products and Services segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, TruProfen, Betsy Farms, PetAction, Minties, Vera and Delightibles. The company generates maximum revenue from Products segment.

Executives

William J. Carter	officer: EVP, GENERAL COUNSEL	C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
John Paul Pearson	officer: EVP, Services & Manufactured	C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Robert Michael Herrman	officer: General Counsel and Secretary	923 SOUTH BRIDGEWAY PLACE, EAGLE ID 83616
Michael A Smith	officer: EVP - Products	923 S. BRIDGEWAY PLACE, C/O PETIQ, INC., EAGLE ID 83616
Kimberly Lefko	director	923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Sheryl Oloughlin	director	923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Scott Huff	director	923. S. BRIDGEWAY PLACE, EAGLE ID 83616
Allan Hall	director	C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Zvi Glasman	officer: Chief Financial Officer	C/O FOX FACTORY HOLDING CORP., 915 DISC DRIVE, SCOTTS VALLEY CA 95066
Kenneth C. Walker	director	C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Susan Sholtis	director	C/O PETIQ, INC., 500 E. SHORE DRIVE, SUITE 120, EAGLE ID 83616
Mccord Christensen	director, officer: Chief Executive Officer	500 EAST SHORE DRIVE, SUITE 120, EAGLE ID 83616
John Newland	officer: Chief Financial Officer	C/O TRUE SCIENCE LLC, 500 E. SHORE DRIVE SUITE 120, EAGLE ID 83616
Ronald Kennedy	director, 10 percent owner	500 EAST SHORE DR, SUITE 120, EAGLE ID 83616
Ecp Helios Partners Iv, L.p.	10 percent owner	437 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022